| Idecabtagene vicleucel in relapsed and refractory multiple myeloma NC Munshi, LD Anderson Jr, N Shah, D Madduri, J Berdeja, S Lonial, ... New England Journal of Medicine 384 (8), 705-716, 2021 | 1463 | 2021 |
| Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label … J San Miguel, K Weisel, P Moreau, M Lacy, K Song, M Delforge, L Karlin, ... The lancet oncology 14 (11), 1055-1066, 2013 | 1014 | 2013 |
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 1007 | 2012 |
| Continuous lenalidomide treatment for newly diagnosed multiple myeloma A Palumbo, R Hajek, M Delforge, M Kropff, MT Petrucci, J Catalano, ... New England Journal of Medicine 366 (19), 1759-1769, 2012 | 912 | 2012 |
| Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA … P Moreau, M Attal, C Hulin, B Arnulf, K Belhadj, L Benboubker, MC Béné, ... The Lancet 394 (10192), 29-38, 2019 | 911 | 2019 |
| Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma L Benboubker, MA Dimopoulos, A Dispenzieri, J Catalano, AR Belch, ... New England Journal of Medicine 371 (10), 906-917, 2014 | 910 | 2014 |
| Neutrophil extracellular trap cell death requires both autophagy and superoxide generation Q Remijsen, TV Berghe, E Wirawan, B Asselbergh, E Parthoens, ... Cell research 21 (2), 290-304, 2011 | 892 | 2011 |
| Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a … M Attal, PG Richardson, SV Rajkumar, J San-Miguel, M Beksac, I Spicka, ... The Lancet 394 (10214), 2096-2107, 2019 | 624* | 2019 |
| Oral selinexor–dexamethasone for triple-class refractory multiple myeloma A Chari, DT Vogl, M Gavriatopoulou, AK Nooka, AJ Yee, CA Huff, ... New England Journal of Medicine 381 (8), 727-738, 2019 | 595 | 2019 |
| Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up MA Dimopoulos, P Moreau, E Terpos, MV Mateos, S Zweegman, G Cook, ... Hemasphere 5 (2), e528, 2021 | 593 | 2021 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 435 | 2016 |
| Teclistamab in relapsed or refractory multiple myeloma P Moreau, AL Garfall, NWCJ van de Donk, H Nahi, JF San-Miguel, A Oriol, ... New England Journal of Medicine 387 (6), 495-505, 2022 | 432 | 2022 |
| Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously … JF San Miguel, R Schlag, NK Khuageva, MA Dimopoulos, O Shpilberg, ... Journal of clinical oncology 31 (4), 448-455, 2013 | 360 | 2013 |
| Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study R Wachter, M Senni, J Belohlavek, E Straburzynska‐Migaj, KK Witte, ... European journal of heart failure 21 (8), 998-1007, 2019 | 359 | 2019 |
| A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with … HM Lokhorst, B van der Holt, S Zweegman, E Vellenga, S Croockewit, ... Blood, The Journal of the American Society of Hematology 115 (6), 1113-1120, 2010 | 335 | 2010 |
| Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study SK Kumar, MA Dimopoulos, E Kastritis, E Terpos, H Nahi, H Goldschmidt, ... Leukemia 31 (11), 2443-2448, 2017 | 323 | 2017 |
| Management of treatment-emergent peripheral neuropathy in multiple myeloma PG Richardson, M Delforge, M Beksaç, P Wen, JL Jongen, O Sezer, ... Leukemia 26 (4), 595-608, 2012 | 310 | 2012 |
| Multiple myeloma: patient outcomes in real‐world practice K Yong, M Delforge, C Driessen, L Fink, A Flinois, S Gonzalez‐McQuire, ... British journal of haematology 175 (2), 252-264, 2016 | 309 | 2016 |
| The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network E Terpos, O Sezer, PI Croucher, R García-Sanz, M Boccadoro, ... Annals of Oncology 20 (8), 1303-1317, 2009 | 282 | 2009 |
| Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma T Facon, MA Dimopoulos, A Dispenzieri, JV Catalano, A Belch, M Cavo, ... Blood, The Journal of the American Society of Hematology 131 (3), 301-310, 2018 | 280 | 2018 |
